Abstract

Objective: To investigate the causes of elevated prostate specific antigen (PSA) levels in patients with lower urinary tract symptoms (LUTS) through transrectal ultrasound guided biopsy (TRUS biopsy), regardless of prostate volume. Methods: Retrospective study was conducted between January 2008 and December 2009 to find the cause of elevated PSA levels in sixty six (N≤66) patients from the outpatient department in Guryyte General Hospital, Aljouf. Age of the patients was between 52 and 90 years and PSA level ranged between 5 ng/ml and 26 ng/ml. All patients were presented with some degree of lower urinary tract symptoms (LUTS) and high PSA levels for age. They underwent TRUS biopsies performed by a Radiologist and Urologist Results: Out of the total sixty six patients, twenty two (33%) of them with a PSA range between 5.1ng/ml and 26 ng/ml were found to have Benign Prostatic Hyperplasia (BPH) and Prostatitis. Eighteen patients (29.5%) with a PSA level between 9.3 ng/ml and 25.6 ng/ml were diagnosed as adenocarcinoma of the prostate. Sixteen patients with PSA between 12ng/ ml and 26 ng/ml were diagnosed as BPH. Ten patients with PSA between 9.3ng/ml and 16 ng/ml were found to have Prostatitis (15.15%). Conclusion: Benign prostate hyperplasia and chronic prostatitis are the two major causes of elevated serum PSA in our cohort followed by prostate cancer. With regards to the PSA level in chronic prostatitis and in prostate cancer, no significant difference was noted. The conclusion reached is that TRUS biopsy is mandatory to determine the exact cause of an elevated PSA level.

Keywords: Prostate hyperplasia · Prostatitis

References

  1. 1.KetchandjiM ,Kuo YF , Shahinian VB , Goodwin JS. Cause of death in older men after diagnosis of prostate cancer .J Am GeriatrSoc.2008 ; 57 : 24 – 30 .
  2. 2.Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, et al. (2011) Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. EurUrol 60: 1045–1054. Prostate Cancer Contribution to Elevated PSA levels, Al Enzi M
  3. 3.Perdona S, Bruzzese D, Ferro M, Autorino R, Marino A, et al. (2013) Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73: 227– 235.
  4. 4.Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostatespecific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581-9.
  5. 5.Hochberg DA, Armenakas NA, Fracchia JA. Relationship of prostatespecific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate 2000;45:315-9.
  6. 6.Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005; 65: 708-12.
  7. 7.Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298:2275-80.
  8. 8.Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M. Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesion .world J urol.2004;22:357-60
  9. 9.Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005; 48: 546-551.
  10. 10.Schröder FH, van der Maas P, Beemsterboer P, Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998; 90(23): 1817-1823.
  11. 11.Andriole GL , Crawford ED , Grubb RL , et al . Mortality results from a randomized prostate-cancer screening trial .N Eng J Med .2009 ; 360 : 1310 – 1319 .
  12. 12.Andriole GL , Crawford ED , Grubb RL , et al . Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up .J Natl Cancer Inst.2012 ; 104 : 125 – 132 .
  13. 13.Lu-Yao G , Albertsen PC , Stanford JL , Stukel TA , Walker-Corkery E , Barry MJ . Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up .J Gen Intern Med 2008 ; 23 : 1809 – 1814 .
  14. 14.IlicD , O’Connor D , Green S , Wilt T . Screening for prostate cancer: a Cochrane systematic review .Cancer Causes Control .2007 ; 18 : 279 – 285 .
  15. 15.CrocettiE ,Ciatto S , Zappa M . Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy .J Natl Cancer Instit.2001; 13  MAJMAAH JOURNAL OF HEALTH SCIENCE, Vol 2, Issue 1, 2014 93 : 876 – 877 .
  16. 16.Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, et al. (2006) Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175: 902–906.
  17. 17.Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
  18. 18.Carvalhal GF, Smith DS, Mager DE. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol. 1999; 161(3): 835-839. Prostate Cancer Contribution to Elevated PSA levels, Al Enzi M 14
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access